In addition, it has been observed that NSCLC patients with tumors harboring a K-RAS mutation showed significantly higher 18F-FDG uptake (SUVmean 9.5) than wild-type K-RAS and a multivariate model based on age, gender, stage and SUVmean might be used as a predictive marker of K-RAS mutation status in patients with stage III or IV NSCLC [34]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.